Herpes Solution Provider, Viradux Research Announces JV Partnership
Summary
Los Angeles, CA, April 26, 2013 --( “This agreement will benefit both organizations while moving forward the effort to significantly improve the lives of those infected with the herpes simplex virus.Improved testing accuracy and availability are the critical first step in this effort.” According to Andrew Bhatnagar of Viradux Research, LTD, “34% of HSV1 infected people are asymptomatic and have no idea that they are unwittingly transmitting this disease.“Our combined goal is to make available a diagnostic tool that, even when deployed to the most remote locations, will allow an affordable, accurate and rapid diagnosis for the many millions of suffers who are overlooked by the current global health care model.” Bhatnager sees this as “an opportunity for Benalli to join forces with the leading edge second generation anti-viral solutions provided by Viradux.Los Angeles, CA, April 26, 2013 --( PR.com )-- Viradux Research, LTD, a provider of anti-herpetic treatment solutions targeted at the rapid resolution of symptoms related to HSV1 and HSV2 infections, announced today that it has reached a joint venture partnership agreement with Benalli of Beijing, China.“Our combined goal is to make available a diagnostic tool that, even when deployed to the most remote locations, will allow an affordable, accurate and rapid diagnosis for the many millions of suffers who are overlooked by the current global health care model.” Bhatnager sees this as “an opportunity for Benalli to join forces with the leading edge second generation anti-viral solutions provided by Viradux.